Díaz Insa, Samuel
Guerrero, Ángel
Viguera, Javier
Medrano Martínez, Vicente
Calle de Miguel, Carlos
Porta-Etessam, Jesús
Ciudad, Antonio
Diaz-Cerezo, Silvia
Roncero Martín, Ana
Núñez, Mercedes http://orcid.org/0000-0003-2675-0945
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 11 December 2023
Accepted: 15 February 2024
First Online: 28 March 2024
Declarations
:
: Vicente Medrano, Jesús Porta-Etessam and Ana Roncero declare that they have no competing interests; Javier Viguera, has received speaker honoraria from Lilly, Lundbeck, Novartis and Teva; Samuel Díaz-Insa has received speaker honoraria from Fundació Universitat-Empresa, Abbie-Allergan, Kern Pharma, Lilly, Lundbeck, Novartis, Organon and Teva and participating in advisory boards from Kern Pharma, Lilly, Lunbeck, Novartis and Teva; Ángel Luís Guerrero has received honoraria for lectures or advisory boards from Allergan-Abbvie, Exeltis, Lilly, Novartis, Lundbeck, Pfizer and Teva, and research support from Abbvie-Allergan, Lilly and Teva; Carlos Calle de Miguel has received speaker honoraria from Asociación Madrileña de Neurología and has received payments to support travel to meetings from Lilly; and Antonio Ciudad, Silvia Díaz-Cerezo and Mercedes Núñez are full time employees at Lilly and minor owners of Lilly shares.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the Good Pharmacoepidemiology Practices (GPPs) guidelines of the International Society for Pharmacoepidemiology, and local rules and regulations. The study protocol was sent to the Spanish Health Authorities for classification and was subsequently evaluated and approved by a central ethics committee (Comité de Ética de la Investigación con Medicamentos del Área de Salud Valladolid Este, Spain). This approval was notified to all the ethics comittees of the participant centers which agreed with the conduction of the study.